Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Misses Expectations By $0.04 EPS

Autolus Therapeutics (NASDAQ:AUTLGet Rating) released its quarterly earnings data on Thursday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04), Fidelity Earnings reports. Autolus Therapeutics had a negative return on equity of 52.44% and a negative net margin of 6,551.06%. During the same quarter last year, the business posted ($0.47) EPS.

Autolus Therapeutics Stock Up 7.1 %

NASDAQ AUTL traded up $0.23 on Friday, hitting $3.48. The stock had a trading volume of 206,112 shares, compared to its average volume of 269,701. Autolus Therapeutics has a one year low of $1.96 and a one year high of $7.90. The stock has a market cap of $316.36 million, a price-to-earnings ratio of -1.77 and a beta of 1.40. The company’s 50-day moving average is $2.72 and its two-hundred day moving average is $3.41.

Analyst Upgrades and Downgrades

AUTL has been the topic of several research reports. Truist Financial dropped their price objective on shares of Autolus Therapeutics from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, June 14th. Needham & Company LLC dropped their price objective on shares of Autolus Therapeutics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC grew its position in Autolus Therapeutics by 6.6% in the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock worth $18,124,000 after purchasing an additional 268,818 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Autolus Therapeutics by 144.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company’s stock worth $1,566,000 after purchasing an additional 222,093 shares during the last quarter. Cetera Investment Advisers grew its position in Autolus Therapeutics by 8.3% in the 1st quarter. Cetera Investment Advisers now owns 124,300 shares of the company’s stock worth $518,000 after purchasing an additional 9,550 shares during the last quarter. Finally, UBS Group AG grew its position in Autolus Therapeutics by 716.1% in the 1st quarter. UBS Group AG now owns 73,858 shares of the company’s stock worth $308,000 after purchasing an additional 64,808 shares during the last quarter. Institutional investors own 61.45% of the company’s stock.

Autolus Therapeutics Company Profile

(Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Recommended Stories

Earnings History for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.